{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:45Z","timestamp":1792839705100,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"publisher","award":["K24DA034621"],"award-info":[{"award-number":["K24DA034621"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>With the advent of efficacious oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV), identification of characteristics associated with adherence is critical to treatment success. We examined correlates of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>ACTG A5360 enrolled HCV treatment-naive persons without decompensated cirrhosis from 5 countries. All participants received a 12-weeks course of sofosbuvir\/velpatasvir at entry. In-person visits occurred at initiation and week 24, sustained virologic response (SVR) assessment. Adherence at week 4 was collected remotely and was dichotomized optimal (100%, no missed doses) versus sub-optimal (&amp;lt;100%). Correlates of sub-optimal adherence were explored using logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 400 participants enrolled; 399 initiated treatment; 395\/397 (99%) reported completing at week 24. Median age was 47 years with 35% female. Among the 368 reporting optimal adherence at week 4 SVR was 96.5% (95% confidence interval [CI] [94.1%, 97.9%]) vs 77.8% (95% CI [59.2%, 89.4%]) P value &amp;lt; .001. In the multivariate model age &amp;lt;30 years and being a US participant were independently associated with early sub-optimal adherence. Participants &amp;lt;30 years were 7.1 times more likely to have early sub-optimal adherence compared to their older counterparts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Self-reported optimal adherence at week 4 was associated with SVR. Early self-reported adherence could be used to identify those at higher risk of treatment failure and may benefit from additional support. Younger individuals &amp;lt;30 years may also be prioritized for additional adherence support.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT03512210.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad034","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T05:39:55Z","timestamp":1674625195000},"page":"1959-1968","source":"Crossref","is-referenced-by-count":10,"title":["Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir\/Velpatasvir in Chronic Hepatitis C Treatment"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-1013","authenticated-orcid":false,"given":"Leonard A","family":"Sowah","sequence":"first","affiliation":[{"name":"Therapeutic Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Smeaton","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard TH Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Brates","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard TH Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debika","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California, Los Angeles , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Linas","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Kreter","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc , Foster City, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Wagner-Cardoso","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Infectologia\u2014Laboratorio de Pesquisa Cl\u00ednica em HIV\/AIDS , Rio de Janeiro , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Solomon","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K","family":"Robbins","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"2023060818544092100_ciad034-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"2023060818544092100_ciad034-B2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/apt.14328","article-title":"Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents","volume":"46","author":"Lin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2023060818544092100_ciad034-B3","first-page":"147","article-title":"Barriers to the treatment of hepatitis C among predominantly African American patients seeking care in an urban teaching hospital in Washington, DC","volume":"113","author":"Liu","year":"2021","journal-title":"J Natl Med Assoc"},{"key":"2023060818544092100_ciad034-B4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/09540121.2021.1889952","article-title":"Barriers to HIV and hepatitis C care for people who inject drugs in Colombia","volume":"34","author":"Borda","year":"2022","journal-title":"AIDS Care"},{"key":"2023060818544092100_ciad034-B5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023060818544092100_ciad034-B6","volume-title":"Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. No. WHO\/CDS\/HIV\/18.4","author":"World Health Organization","year":"2018"},{"key":"2023060818544092100_ciad034-B7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/jvh.13454","article-title":"High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting","volume":"28","author":"Fabbiani","year":"2021","journal-title":"J Viral Hepat"},{"key":"2023060818544092100_ciad034-B8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/liv.13103","article-title":"Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES","volume":"36","author":"Butt","year":"2016","journal-title":"Liver Int"},{"issue":"5 Suppl 3","key":"2023060818544092100_ciad034-B9","first-page":"1","article-title":"A simplified algorithm for the management of hepatitis C infection","volume":"15","author":"Dieterich","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2023060818544092100_ciad034-B10","first-page":"48","article-title":"Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C","volume":"28","author":"Majethia","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2023060818544092100_ciad034-B11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jiaa126","article-title":"Intrahepatic viral kinetics during direct-acting antivirals for hepatitis c in human immunodeficiency virus coinfection: the AIDS Clinical Trials Group A5335S sub study","volume":"222","author":"Balagopal","year":"2020","journal-title":"J Infect Dis"},{"key":"2023060818544092100_ciad034-B12","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023060818544092100_ciad034-B13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023060818544092100_ciad034-B14","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/cid\/ciz1089","article-title":"Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy","volume":"71","author":"Cunningham","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023060818544092100_ciad034-B15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicenter trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023060818544092100_ciad034-B16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2023060818544092100_ciad034-B17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.14266","article-title":"Adherence to pan-genotypic glecaprevir\/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials","volume":"40","author":"Brown","year":"2020","journal-title":"Liver Int"},{"key":"2023060818544092100_ciad034-B18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jvh.12668","article-title":"National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care","volume":"24","author":"El-Akel","year":"2017","journal-title":"J Viral Hepat"},{"key":"2023060818544092100_ciad034-B19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17512433.2017.1383894","article-title":"Pathways to the elimination of hepatitis C: prioritising access for all","volume":"10","author":"Pedrana","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2023060818544092100_ciad034-B20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jgh.15228","article-title":"Barriers to hepatitis C direct-acting antiviral therapy among HIV\/hepatitis C virus-coinfected persons","volume":"36","author":"Jatt","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2023060818544092100_ciad034-B21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz316","article-title":"Expanding hepatitis C virus care and cure: national experience using a clinical pharmacist\u2013driven model","volume":"6","author":"Koren","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023060818544092100_ciad034-B22","first-page":"697","article-title":"Direct-acting antivirals for hepatitis C: predictors of early discontinuation in the real world","volume":"25","author":"de \u00c1vila Machado","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2023060818544092100_ciad034-B23","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s10620-019-05590-x","article-title":"Determinants of hepatitis C treatment adherence and treatment completion among veterans in the direct acting antiviral era","volume":"64","author":"Patel","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2023060818544092100_ciad034-B24","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00002030-200401001-00004","article-title":"Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse","volume":"18","author":"Hinkin","year":"2004","journal-title":"AIDS"},{"key":"2023060818544092100_ciad034-B25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/00325481.2020.1749499","article-title":"Patient factors associated with diabetes medication adherence at different health literacy levels: a cross-sectional study at a family medicine clinic","volume":"132","author":"Huang","year":"2020","journal-title":"Postgrad Med"},{"key":"2023060818544092100_ciad034-B26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/apc.2017.0315","article-title":"Acceptability of mobile phone-based nurse-delivered counseling intervention to improve HIV treatment adherence and self-care behaviors among HIV-positive women in India","volume":"32","author":"Duggal","year":"2018","journal-title":"AIDS Patient Care STDS"},{"key":"2023060818544092100_ciad034-B27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11904-021-00568-9","article-title":"A review of interventions to enhance HIV medication adherence","volume":"18","author":"Whiteley","year":"2021","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad034\/49446698\/ciad034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1959\/50541655\/ciad034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1959\/50541655\/ciad034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T18:55:54Z","timestamp":1686250554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/11\/1959\/7000590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,1,24]]},"published-print":{"date-parts":[[2023,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad034","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,1,24]]}}}